CIP2A and breast carcinoma: Moreover, our previous studies also revealed that CIP2A plays a critical role in the sensitivity of TD52 (an erlotinib derivative) as well as bortezomib in breast cancer and liver cancer (Chen et al., 2010; Liu et al., 2017; Tseng et al., 2012), suggesting that CIP2A signaling is a promising target for cancer therapy.